FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / Vaccine / Venezuelan equine encephalitis virus vaccine candidate (V352...
Vaccine2006; 25(10); 1868-1876; doi: 10.1016/j.vaccine.2006.10.030

Venezuelan equine encephalitis virus vaccine candidate (V3526) safety, immunogenicity and efficacy in horses.

Abstract: A new vaccine, V3526, is a live-attenuated virus derived by site-directed mutagenesis from a virulent clone of the Venezuelan equine encephalitis virus (VEEV) IA/B Trinidad donkey (TrD) strain, intended for human use in protection against Venezuelan equine encephalitis (VEE). Two studies were conducted in horses to evaluate the safety, immunogenicity, ability to boost and protective efficacy of V3526 against challenges of TrD and VEEV IE 64A99. Horses were vaccinated subcutaneously (SC) with 10(7), 10(5), 10(3) or 10(2) plaque-forming units (pfu) of V3526. Control horses were sham immunized. In the first study, challenge viruses (TrD or 64A99) were administered SC 28 days post-vaccination (PV). No viremia and only mild fluctuation in white blood cell counts were observed PV. None of the V3526 vaccinated horses showed clinical signs of disease or pathology of VEE post-challenge (PC). In contrast, control horses challenged SC with 10(4)pfu TrD became viremic and showed classical signs of VEE beginning on Day 3 PC, including elevated body temperature, anorexia, leukopenia and malaise. Moderate to severe encephalitis was found in three of five control horses challenged with TrD. Control horses challenged with 64A99 failed to develop detectable viremia, but did exhibit a brief febrile episode at 1-3 days PC. None of the 10 immunized horses challenged with 64A99 became pyrexic. Twenty four of 25 horses immunized with V3526 in the first study developed serum neutralizing antibody to TrD and 64A99 within 14 days PV. Vaccinations with V3526, at doses as low as 10(2)pfu, were safe and efficacious in protecting horses against a virulent TrD virus challenge. The second study supported that repeat dosing resulted in an increase in serum neutralizing antibody to TrD.
Get Full Text
Publication Date: 2006-10-27 PubMed ID: 17240002DOI: 10.1016/j.vaccine.2006.10.030Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Clinical Trial
  • Journal Article
  • Research Support
  • U.S. Gov't
  • Non-P.H.S.

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The research paper describes the development of a new vaccine against the Venezuelan equine encephalitis virus (VEEV), termed V3526. This vaccine, designed for humans, was evaluated for its safety, efficacy, and immune response in horses. The findings indicated that the vaccine is safe and effective even at low doses, and repeat dosing led to an increased immune response.

Overview of the Study

  • The research paper discusses two studies carried out to evaluate the safety, immune response, and efficacy of a new vaccine, V3526, that aims to provide protection against Venezuelan Equine Encephalitis (VEE). This new vaccine is a live-attenuated virus derived by site-directed mutagenesis from a virulent clone of the VEEV.
  • The studies were conducted on horses, which were vaccinated subcutaneously with varying doses of V3526. Another group of control horses were sham immunized, meaning they were given a fake or placebo vaccine. Following vaccination, the horses were challenged with either a TrD or 64A99 strain of VEEV.

Study Results

  • Post-vaccination results showed no viremia, or presence of viruses in the blood, and only slight fluctuations in white blood cell counts. Importantly, no clinical signs of VEE disease were observed in the vaccinated horses post-challenge.
  • In stark contrast, control horses showed signs of VEE disease, including fever, loss of appetite, leukopenia (low white blood cell count), and general discomfort. Among the control group, those challenged with the TrD strain even developed moderate to severe encephalitis or brain inflammation. While those challenged with the 64A99 strain didn’t develop detectable viremia, they exhibited brief fever episodes.
  • The study found that nearly all the horses vaccinated with V3526 developed serum neutralizing antibodies against both the TrD and 64A99 strains within 14 days post-vaccination. These antibodies are essential components of the immune system that neutralize viruses, thereby suggesting a successful immune response.
  • The low dose vaccinations of V3526, as low as 10(2) plaque-forming units, were found to be safe and efficacious in protecting horses against a virulent TrD virus challenge.

Additional Findings and Conclusions

  • The second phase of the study corroborated the findings of the first, additionally indicating that repeat dosing of the vaccine led to an increase in serum neutralizing antibody to TrD. This suggests that the vaccine’s effectiveness could potentially be boosted through additional doses.
  • Taken together, the research demonstrates the potential effectiveness of the V3526 vaccine in combating VEEV. However, it’s worth noting that this study was carried out on horses, hence further research will be needed to test its safety and efficacy in humans.

Cite This Article

APA
Fine DL, Roberts BA, Teehee ML, Terpening SJ, Kelly CL, Raetz JL, Baker DC, Powers AM, Bowen RA. (2006). Venezuelan equine encephalitis virus vaccine candidate (V3526) safety, immunogenicity and efficacy in horses. Vaccine, 25(10), 1868-1876. https://doi.org/10.1016/j.vaccine.2006.10.030

Publication

Vaccine
ISSN: 0264-410X
NlmUniqueID: 8406899
Country: Netherlands
Language: English
Volume: 25
Issue: 10
Pages: 1868-1876

Researcher Affiliations

Fine, Donald L
  • DynPort Vaccine Company LLC (DVC), A CSC Company, 64 Thomas Johnson Drive, Frederick, MD 21702, USA. dfine@csc.com
Roberts, Brian A
    Teehee, Max L
      Terpening, Sara J
        Kelly, Cindy L H
          Raetz, Janae L
            Baker, Dale C
              Powers, Ann M
                Bowen, Richard A

                  MeSH Terms

                  • Animals
                  • Encephalitis Virus, Venezuelan Equine / immunology
                  • Encephalitis Virus, Venezuelan Equine / isolation & purification
                  • Encephalomyelitis, Venezuelan Equine / pathology
                  • Encephalomyelitis, Venezuelan Equine / physiopathology
                  • Encephalomyelitis, Venezuelan Equine / prevention & control
                  • Female
                  • Histocytochemistry
                  • Horse Diseases / prevention & control
                  • Horses
                  • Injections, Subcutaneous
                  • Kidney / pathology
                  • Leukocyte Count
                  • Liver / pathology
                  • Lung / pathology
                  • Lymph Nodes / pathology
                  • Male
                  • Myocardium / pathology
                  • Pancreas / pathology
                  • Spleen / pathology
                  • Telencephalon / pathology
                  • Vaccines, Attenuated / adverse effects
                  • Vaccines, Attenuated / immunology
                  • Viral Plaque Assay
                  • Viral Vaccines / adverse effects
                  • Viral Vaccines / immunology
                  • Viremia / prevention & control

                  Citations

                  This article has been cited 22 times.
                  1. Bonilla-Aldana DK, Bonilla Carvajal CD, Moreno-Ramos E, Barboza JJ, Rodriguez-Morales AJ. Mapping Eastern (EEE) and Venezuelan Equine Encephalitides (VEE) among Equines Using Geographical Information Systems, Colombia, 2008-2019. Viruses 2023 Mar 8;15(3).
                    doi: 10.3390/v15030707pubmed: 36992416google scholar: lookup
                  2. Babaeimarzangou SS, Zaker H, Soleimannezhadbari E, Gamchi NS, Kazeminia M, Tarighi S, Seyedian H, Tsatsakis A, Spandidos DA, Margina D. Vaccine development for zoonotic viral diseases caused by positive‑sense single‑stranded RNA viruses belonging to the Coronaviridae and Togaviridae families (Review). Exp Ther Med 2023 Jan;25(1):42.
                    doi: 10.3892/etm.2022.11741pubmed: 36569444google scholar: lookup
                  3. Haines CA, Campos RK, Azar SR, Warmbrod KL, Kautz TF, Forrester NL, Rossi SL. Venezuelan Equine Encephalitis Virus V3526 Vaccine RNA-Dependent RNA Polymerase Mutants Increase Vaccine Safety Through Restricted Tissue Tropism in a Murine Model. Zoonoses (Burlingt) 2022;2.
                    doi: 10.15212/zoonoses-2021-0016pubmed: 35262074google scholar: lookup
                  4. Sharma A, Knollmann-Ritschel B. Current Understanding of the Molecular Basis of Venezuelan Equine Encephalitis Virus Pathogenesis and Vaccine Development. Viruses 2019 Feb 18;11(2).
                    doi: 10.3390/v11020164pubmed: 30781656google scholar: lookup
                  5. Agnihothram S, Menachery VD, Yount BL Jr,, Lindesmith LC, Scobey T, Whitmore A, Schäfer A, Heise MT, Baric RS. Development of a Broadly Accessible Venezuelan Equine Encephalitis Virus Replicon Particle Vaccine Platform. J Virol 2018 Jun 1;92(11).
                    doi: 10.1128/JVI.00027-18pubmed: 29540599google scholar: lookup
                  6. Beall A, Yount B, Lin CM, Hou Y, Wang Q, Saif L, Baric R. Characterization of a Pathogenic Full-Length cDNA Clone and Transmission Model for Porcine Epidemic Diarrhea Virus Strain PC22A. mBio 2016 Jan 5;7(1):e01451-15.
                    doi: 10.1128/mBio.01451-15pubmed: 26733065google scholar: lookup
                  7. Chung DH, Jonsson CB, Tower NA, Chu YK, Sahin E, Golden JE, Noah JW, Schroeder CE, Sotsky JB, Sosa MI, Cramer DE, McKellip SN, Rasmussen L, White EL, Schmaljohn CS, Julander JG, Smith JM, Filone CM, Connor JH, Sakurai Y, Davey RA. Discovery of a novel compound with anti-venezuelan equine encephalitis virus activity that targets the nonstructural protein 2. PLoS Pathog 2014 Jun;10(6):e1004213.
                    doi: 10.1371/journal.ppat.1004213pubmed: 24967809google scholar: lookup
                  8. Wolfe DN, Heppner DG, Gardner SN, Jaing C, Dupuy LC, Schmaljohn CS, Carlton K. Current strategic thinking for the development of a trivalent alphavirus vaccine for human use. Am J Trop Med Hyg 2014 Sep;91(3):442-50.
                    doi: 10.4269/ajtmh.14-0055pubmed: 24842880google scholar: lookup
                  9. Go YY, Balasuriya UB, Lee CK. Zoonotic encephalitides caused by arboviruses: transmission and epidemiology of alphaviruses and flaviviruses. Clin Exp Vaccine Res 2014 Jan;3(1):58-77.
                    doi: 10.7774/cevr.2014.3.1.58pubmed: 24427764google scholar: lookup
                  10. Agnihothram S, Gopal R, Yount BL Jr, Donaldson EF, Menachery VD, Graham RL, Scobey TD, Gralinski LE, Denison MR, Zambon M, Baric RS. Evaluation of serologic and antigenic relationships between middle eastern respiratory syndrome coronavirus and other coronaviruses to develop vaccine platforms for the rapid response to emerging coronaviruses. J Infect Dis 2014 Apr 1;209(7):995-1006.
                    doi: 10.1093/infdis/jit609pubmed: 24253287google scholar: lookup
                  11. Monath TP. Vaccines against diseases transmitted from animals to humans: a one health paradigm. Vaccine 2013 Nov 4;31(46):5321-38.
                    doi: 10.1016/j.vaccine.2013.09.029pubmed: 24060567google scholar: lookup
                  12. Rossi SL, Guerbois M, Gorchakov R, Plante KS, Forrester NL, Weaver SC. IRES-based Venezuelan equine encephalitis vaccine candidate elicits protective immunity in mice. Virology 2013 Mar 15;437(2):81-8.
                    doi: 10.1016/j.virol.2012.11.013pubmed: 23351391google scholar: lookup
                  13. Tretyakova I, Lukashevich IS, Glass P, Wang E, Weaver S, Pushko P. Novel vaccine against Venezuelan equine encephalitis combines advantages of DNA immunization and a live attenuated vaccine. Vaccine 2013 Feb 4;31(7):1019-25.
                    doi: 10.1016/j.vaccine.2012.12.050pubmed: 23287629google scholar: lookup
                  14. Parker MD, Buckley MJ, Melanson VR, Glass PJ, Norwood D, Hart MK. Antibody to the E3 glycoprotein protects mice against lethal venezuelan equine encephalitis virus infection. J Virol 2010 Dec;84(24):12683-90.
                    doi: 10.1128/JVI.01345-10pubmed: 20926570google scholar: lookup
                  15. Ramasamy S, Liu CQ, Tran H, Gubala A, Gauci P, McAllister J, Vo T. Principles of antidote pharmacology: an update on prophylaxis, post-exposure treatment recommendations and research initiatives for biological agents. Br J Pharmacol 2010 Oct;161(4):721-48.
                    doi: 10.1111/j.1476-5381.2010.00939.xpubmed: 20860656google scholar: lookup
                  16. Hunt AR, Frederickson S, Maruyama T, Roehrig JT, Blair CD. The first human epitope map of the alphaviral E1 and E2 proteins reveals a new E2 epitope with significant virus neutralizing activity. PLoS Negl Trop Dis 2010 Jul 13;4(7):e739.
                    doi: 10.1371/journal.pntd.0000739pubmed: 20644615google scholar: lookup
                  17. Martin SS, Bakken RR, Lind CM, Garcia P, Jenkins E, Glass PJ, Parker MD, Hart MK, Fine DL. Evaluation of formalin inactivated V3526 virus with adjuvant as a next generation vaccine candidate for Venezuelan equine encephalitis virus. Vaccine 2010 Apr 19;28(18):3143-51.
                    doi: 10.1016/j.vaccine.2010.02.056pubmed: 20193792google scholar: lookup
                  18. Martin SS, Bakken RR, Lind CM, Garcia P, Jenkins E, Glass PJ, Parker MD, Hart MK, Fine DL. Comparison of the immunological responses and efficacy of gamma-irradiated V3526 vaccine formulations against subcutaneous and aerosol challenge with Venezuelan equine encephalitis virus subtype IAB. Vaccine 2010 Jan 22;28(4):1031-40.
                    doi: 10.1016/j.vaccine.2009.10.126pubmed: 19914193google scholar: lookup
                  19. Fine DL, Jenkins E, Martin SS, Glass P, Parker MD, Grimm B. A multisystem approach for development and evaluation of inactivated vaccines for Venezuelan equine encephalitis virus (VEEV). J Virol Methods 2010 Feb;163(2):424-32.
                    doi: 10.1016/j.jviromet.2009.11.006pubmed: 19903494google scholar: lookup
                  20. Lu S, Wang S. Technical transformation of biodefense vaccines. Vaccine 2009 Nov 5;27 Suppl 4(0 4):D8-D15.
                    doi: 10.1016/j.vaccine.2009.08.055pubmed: 19837293google scholar: lookup
                  21. Martin SS, Bakken RR, Lind CM, Reed DS, Price JL, Koeller CA, Parker MD, Hart MK, Fine DL. Telemetric analysis to detect febrile responses in mice following vaccination with a live-attenuated virus vaccine. Vaccine 2009 Nov 16;27(49):6814-23.
                    doi: 10.1016/j.vaccine.2009.09.013pubmed: 19761841google scholar: lookup
                  22. Espinosa BJ, Weaver SC, Paessler S, Brining D, Salazar M, Kochel T. Susceptibility of the Aotus nancymaae owl monkey to eastern equine encephalitis. Vaccine 2009 Mar 10;27(11):1729-34.
                    doi: 10.1016/j.vaccine.2009.01.029pubmed: 19186197google scholar: lookup
                  Subscribe to our newsletter
                  Join 99,344 horse owners like you who receive our email updates on horse health and nutrition.